Xellia Pharmaceuticals ApS:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Xellia Pharmaceuticals ApS - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C11157)・商品コード:DATA904C11157
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:26
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Xellia Pharmaceuticals ApS (Xellia), a subsidiary of Novo A/S is a healthcare products provider that offers fermented and semi-synthetic APIs and injectable finished dosage forms. The company offers strain and fermentation development with bacteria and fungi. It provides injectable products in the form of liquids, aseptically filled dry powders or in the form of freeze-dried powders; and inhalable products. Xellia offers products in therapeutic areas including gram-negative infections, gram-positive infections, resistance scare in healthcare, pathogenic microorganisms and fungal infections. The company operates manufacturing facilities in Denmark, the US, Hungary and China. Xellia is headquartered in Copenhagen, Denmark.

Xellia Pharmaceuticals ApS – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Xellia Pharmaceuticals ApS, Medical Devices Deals, 2012 to YTD 2018 9
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Xellia Acquires Lyophilized Manufacturing Facility from Fresenius Kabi 11
Partnerships 12
Leukocare and Xellia Pharma Enter into Partnership Agreement 12
Xellia Pharma, SINTEF Materials And Statens Serum Institut Enter Into Agreement To Develop New Antibiotics 13
Acquisition 14
Novo Acquires Xellia Pharma for USD700 Million 14
Xellia Pharmaceuticals ApS – Key Competitors 16
Xellia Pharmaceuticals ApS – Key Employees 17
Xellia Pharmaceuticals ApS – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Joint Venture 18
Recent Developments 19
Strategy And Business Planning 19
Sep 18, 2018: Xellia Pharmaceuticals Opens North American Commercial Office in Chicago Ahead of Launching Value-Added Anti-Infective Injectable Drug Products 19
Oct 11, 2017: Xellia Pharmaceuticals Expands its Global Specialty Anti-infective Product Manufacturing Capabilities with a US$25m Investment in its Copenhagen Site 21
Aug 22, 2017: Xellia Pharmaceuticals Completes Expansion of its Budapest Facilities, Strengthening its Global Anti-infective Product Capabilities 22
Financial Announcements 23
Mar 21, 2018: Xellia Pharmaceuticals Reports on Strong 2017 Financial Results and Advances in the Development of its Novel Premixed Vancomycin Ready-to-Use (RTU) Bag 23
Corporate Communications 24
Jun 13, 2018: Xellia Pharmaceuticals Names Matthew Anderson As Chief Financial Officer 24
Other Significant Developments 25
Jan 18, 2017: Xellia Pharmaceuticals Signs Davos Declaration on Combating Antimicrobial Resistance 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Key Facts 2
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Xellia Pharmaceuticals ApS, Deals By Therapy Area, 2012 to YTD 2018 8
Xellia Pharmaceuticals ApS, Medical Devices Deals, 2012 to YTD 2018 9
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Xellia Acquires Lyophilized Manufacturing Facility from Fresenius Kabi 11
Leukocare and Xellia Pharma Enter into Partnership Agreement 12
Xellia Pharma, SINTEF Materials And Statens Serum Institut Enter Into Agreement To Develop New Antibiotics 13
Novo Acquires Xellia Pharma for USD700 Million 14
Xellia Pharmaceuticals ApS, Key Competitors 16
Xellia Pharmaceuticals ApS, Key Employees 17
Xellia Pharmaceuticals ApS, Subsidiaries 18
Xellia Pharmaceuticals ApS, Joint Venture 18

List of Figures
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Xellia Pharmaceuticals ApS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Xellia Pharmaceuticals ApS, Medical Devices Deals, 2012 to YTD 2018 9

★調査レポート[Xellia Pharmaceuticals ApS:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C11157)販売に関する免責事項を必ずご確認ください。
★調査レポート[Xellia Pharmaceuticals ApS:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆